PRFX (PRF Technologies) Additional Paid-In Capital: $79.96 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PRFX PRF Technologies Ltd PRFX
22 GF Score
Price $0.93
! 1 Warning Sign
View Full Analysis

What is PRF Technologies Additional Paid-In Capital?

PRF Technologies PRFX -2.38% 22 Additional Paid-In Capital is $79.96 Mil as of Jun. 2026. GuruFocus rates PRFX with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.


PRF Technologies's quarterly additional paid-in capital increased from Jun. 2025 ($67.21 Mil) to Dec. 2025 ($69.83 Mil) and increased from Dec. 2025 ($69.83 Mil) to Jun. 2026 ($79.96 Mil).

PRF Technologies's annual additional paid-in capital increased from Dec. 2023 ($49.10 Mil) to Dec. 2024 ($58.28 Mil) and increased from Dec. 2024 ($58.28 Mil) to Dec. 2025 ($69.83 Mil).

PRF Technologies Additional Paid-In Capital Related Terms

PRF Technologies Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for PRF Technologies's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PRF Technologies Additional Paid-In Capital Chart

PRF Technologies Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial 41.72 43.45 49.10 58.28 69.83

PRF Technologies Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.35 58.28 67.21 69.83 79.96
PRFX
22GF Score
PRF Technologies Ltd PRFX
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PRF Technologies Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $79.96 Mil mean?
PRF Technologies (PRFX) has a Additional Paid-In Capital of $79.96 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on PRF Technologies and its competitors.
Is PRF Technologies' Additional Paid-In Capital too high?
PRF Technologies' current Additional Paid-In Capital is $79.96 Mil. Overall, PRF Technologies has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does PRF Technologies' Additional Paid-In Capital compare to CTTH and UPC?
PRF Technologies' Additional Paid-In Capital of $79.96 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Drug Manufacturers company?
A good Additional Paid-In Capital depends on the Drug Manufacturers industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on PRF Technologies and its competitors. PRF Technologies's current Additional Paid-In Capital is $79.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PRF Technologies stock overvalued right now?
PRF Technologies (PRFX) has a current Additional Paid-In Capital of $79.96 Mil. The current Additional Paid-In Capital is $79.96 Mil. PRF Technologies' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For PRF Technologies (PRFX), the current Additional Paid-In Capital is $79.96 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PRF Technologies Business Description

Address 65 Yigal Alon Street, Tel Aviv, ISR, 6744316
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.
22GF Score

Get the complete analysis for PRFX

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.93
Price